FIELD: biotechnology; medicine.
SUBSTANCE: invention discloses a new antitumor agent containing (S)-N-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizin-8-yl) acrylamide (compound (A) or a pharmaceutically acceptable salt thereof.
EFFECT: invention may be used to the treatment of a patient having a resistant malignant tumor expressing a mutant EGFR having at least one mutation selected from the group L792H, L792F, L792Y and L718Q.
21 cl, 1 ex, 1 tbl, 1 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| SELECTIVE INHIBITOR OF EGFR HAVING MUTATION IN EXON 18 AND/OR EXON 21 | 2018 |
|
RU2785657C2 |
| SELECTIVE EGFR MUTANT INHIBITOR WITH INSERTION IN EXON 20 | 2017 |
|
RU2774629C2 |
| 7H-PYRROLO[2,3-D]PYRIMIDINE-4-AMINE DERIVATIVE | 2020 |
|
RU2796605C2 |
| T-CELL RECEPTOR CONSTRUCTS AND THEIR USE | 2019 |
|
RU2785954C2 |
| CONJUGATES OF CMET ANTIBODY AND DRUG AND METHODS OF USING | 2017 |
|
RU2740996C2 |
| BISPECIFIC ANTIGEN-BINDING PROTEIN EGFR/CD16 | 2019 |
|
RU2792240C2 |
| COMPOSITIONS AND METHODS OF TREATMENT OF CANCER WITH BRAF ATYPICAL MUTATIONS | 2018 |
|
RU2812706C2 |
| NEOANTIGENS AND THEIR USE | 2019 |
|
RU2813924C2 |
| NEOANTIGENS AND THEIR APPLICATION METHODS | 2017 |
|
RU2773273C2 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
